Results from this study also highlight the importance of HER-2/neu or PI3K/Akt components, including GSK-3β, β-catenin, cyclin D1 and p21WAF1, which may serve as future targets for the development of therapeutic strategies against HER-2/neu-overexpressing breast cancer. This evidence concerns the gene AKT1 and breast carcinoma.